Design, synthesis, and biological evaluation of novel HDAC/CD13 dual inhibitors for the treatment of cancer

  • Eur J Med Chem. 2023 Nov 15;260:115752. doi: 10.1016/j.ejmech.2023.115752.
Geng Jia  1 ,  Kangjing Qi  1 ,  Baogeng Hou  1 ,  Kairui Yue  1 ,  Tongqiang Xu  2 ,  Yuqi Jiang  3 ,  Xiaoyang Li  4
Affiliations
  • 1. Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, 5 Yushan Road, Qingdao, 266003, China.
  • 2. Marine Biomedical Research Institute of Qingdao, Qingdao, Shandong, 266071, PR China.
  • 3. Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, 5 Yushan Road, Qingdao, 266003, China; Center for Targeted Protein Degradation and Drug Discovery, Ocean University of China, Qingdao, Shandong, 266003, China; Marine Biomedical Research Institute of Qingdao, Qingdao, Shandong, 266071, PR China. Electronic address: [email protected].
  • 4. Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, 5 Yushan Road, Qingdao, 266003, China; Center for Targeted Protein Degradation and Drug Discovery, Ocean University of China, Qingdao, Shandong, 266003, China; Marine Biomedical Research Institute of Qingdao, Qingdao, Shandong, 266071, PR China. Electronic address: [email protected].
PMID: 37647727 DOI: 10.1016/j.ejmech.2023.115752
Abstract

Aminopeptidase N (APN/CD13) plays a role in tumors progression, but its inhibitor lacks cytotoxicity and is used as an Adjuvant drug in Cancer treatment. Histone deacetylases (HDACs) are a type of epigenetic targets, and HDAC inhibitors are cytotoxic and exhibit synergistic effects with other Anticancer agents. Herein, a novel series of HDAC/CD13 dual inhibitors were rationally designed and synthesized to combine the anti-metastasis and anti-invasion of CD13 Inhibitor with the cytotoxic of HDAC Inhibitor. The representative compound 12 exhibited more potent inhibitory activity against human CD13, HDAC1-3, and antiproliferative activity than positive controls bestatin and SAHA. Compound 12 effectively induced Apoptosis in MV4-11 cells, while arresting A549 cells in G2/M phase. Moreover, 12 exhibited significantly better anti-metastasis and anti-invasion effects than mono-inhibitors 32 and 38, indicating that it is a promising anti-cancer agent for further investigation.

Keywords
CD13 inhibitor; Cancer; Dual inhibitor; HDAC inhibitor; Rational drug design.
Products